

Cleveland Clinic adopts CT:VQ™

19 December 2025

Highlights

- Cleveland Clinic, one of the most prestigious healthcare institutions globally, commences clinical use of CT:VQ™
- Cleveland Clinic becomes third major U.S. academic medical centre (AMC) to adopt CT:VQ™, following Stanford and University of Miami
- Third leading AMC deployment achieved within three months of FDA clearance, validating 4DMedical's commercialisation strategy
- Arrangement provides one month of introductory pricing prior to full commercial terms

Melbourne, Australia, 19 December 2025: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company") a global leader in respiratory imaging technology, today announces that Cleveland Clinic has entered into a commercial arrangement for the clinical use of CT:VQ™.

CT:VQ™ commercial launch at Cleveland Clinic

Cleveland Clinic, consistently ranked among the top hospitals in the United States and recognised globally for clinical excellence, has entered into a commercial arrangement for CT:VQ™. The agreement follows 4DMedical's proven commercialisation model, providing an introductory pricing period (one month) to support clinical workflow integration, followed by full commercial terms.

Cleveland Clinic's adoption of CT:VQ™ represents a major milestone in 4DMedical's strategy to establish CT:VQ™ as the standard of care at leading academic medical centres. As one of the most prestigious and influential healthcare institutions in the United States, Cleveland Clinic's deployment will serve as a critical reference site, demonstrating CT:VQ™'s clinical utility and operational advantages to the broader U.S. hospital market.

The commercial launch at Cleveland Clinic follows 4DMedical's recent successes at Stanford University and University of Miami, establishing a growing network of premier academic medical centres deploying CT:VQ™ for advanced respiratory diagnostics.

4DMedical MD/CEO and Founder Andreas Fouras said:

Securing Cleveland Clinic as a CT:VQ™ customer is a major milestone for 4DMedical. Cleveland Clinic is one of the most respected healthcare institutions in the world, and their decision to deploy CT:VQ™ validates both our technology and our commercialisation strategy.

In just over three months since FDA clearance, we've established CT:VQ™ at three of America's leading academic medical centres: Stanford, University of Miami, and Cleveland Clinic. This rapid adoption by elite institutions demonstrates the compelling clinical and operational advantages of CT:VQ™ over traditional nuclear VQ imaging.

Our AMC-focused strategy is working exactly as planned. These prestigious institutions serve as powerful reference sites that, combined with the Philips partnership, provide the platform to accelerate adoption across national health systems and community hospitals.

The momentum is extraordinary, and we're just getting started.

The future of
lung health

Melbourne
Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles
21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**® transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

For personal use only